Over the past few years, we have developed an increased understanding of the molecular mechanisms that underlie prostate cancer progression and castration resistance and expanded our repertoire of therapeutic options for castration-resistant prostate cancer (CRPC).
Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, and radium-233) have been shown to prolong overall survival in patients with CRPC in the postchemotherapy setting. Targeting the androgen receptor pathway continues to have an important role in the treatment of CRPC, with abiraterone acetate and enzalutamide being the most exciting developments. Cabazitaxel is now considered the standard-of-care second-line chemotherapy for men with metastatic CRPC (mCRPC). Bone-targeted therapy is an active area of research, with denosumab being the first bone-targeted agent able to significantly delay the appearance of bone metastases in patients with CRPC and radium-223 being the first radiopharmaceutical agent to improve survival in patients with mCRPC.
Written by:
Bishr M, Saad F. Are you the author?
Centre de Recherche, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montréal, QC H2L 4M1, Canada.
Reference: Nat Rev Urol. 2013 Jun 25. Epub ahead of print.
doi: 10.1038/nrurol.2013.137
PubMed Abstract
PMID: 23797341
